+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy



Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy



International Journal of Nanomedicine 14: 1489-1501



Antiangiogenic drugs usually have short-acting efficacy and poor treatment compliance. The purpose of this study was to determine whether mesoporous silica nanoparticles (MSNs) could be utilized as a nanodrug delivery system for improving antiangiogenic therapy. MSN-encapsulated bevacizumab nanoparticles were prepared by the nanocasting strategy and characterized by Fourier transform infrared, transmission electron microscopy, and Brunauer-Emmett-Teller method. Encapsulation efficiency and drug loading efficiency of MSN-encapsulated bevacizumab nanoparticles were calculated. The pharmacokinetics, cytotoxicity, and tissue toxicity were evaluated in vitro and in vivo. The antiangiogenic effects of MSN-bevacizumab nanoparticles were evaluated in vitro and in vivo. MSN encapsulation could prolong the residency of bevacizumab in vitreous/aqueous humor and maintain the long-lasting drug concentration. MSN-encapsulated bevacizumab nanoparticles did not show any obvious cytotoxicity and tissue toxicity. MSN-encapsulated bevacizumab nanoparticles were more effective than bevacizumab in suppressing vascular endothelial growth factor-induced endothelial cell proliferation, migration, and tube formation in vitro. MSN-encapsulated bevacizumab nanoparticles showed sustained inhibitory effects on corneal neovascularization and retinal neovascularization in vivo. This study provides a novel strategy of encapsulating bevacizumab to protect and deliver it, which could increase the time between administration and formulation shelf-life. MSN-encapsulated bevacizumab is a promising drug delivery alternative of antiangiogenic therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066598268

Download citation: RISBibTeXText

PMID: 30880960

DOI: 10.2147/ijn.s195504


Related references

Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Nanotechnology 26(14): 145102, 2015

Trivalent galactosyl-functionalized mesoporous silica nanoparticles as a target-specific delivery system for boron neutron capture therapy. Nanoscale 5(19): 9412-9418, 2013

Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy. Drug Delivery 24(1): 681-691, 2017

Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells. Oncology Reports 38(3): 1442-1450, 2017

Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery. Nanomedicine 12(7): 1951-1959, 2016

Mesoporous silica nanoparticles as a promising skin delivery system for methotrexate. International Journal of Pharmaceutics 530(1-2): 239-248, 2017

Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3(8): 1341-1346, 2007

Mesoporous silica nanoparticles as a compound delivery system in zebrafish embryos. International Journal of Nanomedicine 7: 1875-1890, 2012

Mesoporous silica nanoparticles in target drug delivery system: A review. International Journal of Pharmaceutical Investigation 5(3): 124-133, 2015

Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. International Journal of Pharmaceutics 423(2): 509-515, 2012

Dual targeting delivery of miR-328 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. Nanomedicine 2018:, 2018

Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. International Journal of Nanomedicine 13: 1241-1256, 2018

An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 31(12): 3335-3346, 2010

A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy. Chemical Biology and Drug Design 92(2): 1435-1444, 2018

Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. European Journal of Pharmaceutical Sciences 111: 492-502, 2018